Literature DB >> 14966263

Psoralen interstrand cross-link repair is specifically altered by an adjacent triple-stranded structure.

F Guillonneau1, A L Guieysse, S Nocentini, C Giovannangeli, D Praseuth.   

Abstract

Targeting DNA-damaging agents to specific DNA sites by using sequence-specific DNA ligands has been successful in directing genomic modifications. The understanding of repair processing of such targeted damage and the influence of the adjacent complex is largely unknown. In this way, directed interstrand cross-links (ICLs) have already been generated by psoralen targeting. The mechanisms responsible for ICL removal are far from being understood in mammalian cells, with the proposed involvement of both mutagenic and recombinogenic pathways. Here, a unique ICL was introduced at a selected site by photoactivation of a psoralen moiety with the use of psoralen conjugates of triplex-forming oligonucleotides. The processing of psoralen ICL was evaluated in vitro and in cells for two types of cross-linked substrates, either containing a psoralen ICL alone or with an adjacent triple-stranded structure. We show that the presence of a neighbouring triplex structure interferes with different stages of psoralen ICL processing: (i) the ICL-induced DNA repair synthesis in HeLa cell extracts is inhibited by the triplex structure, as measured by the efficiency of 'true' and futile repair synthesis, stopping at the ICL site; (ii) in HeLa cells, the ICL removal via a nucleotide excision repair (NER) pathway is delayed in the presence of a neighbouring triplex; and (iii) the binding to ICL of recombinant xeroderma pigmentosum A protein, which is involved in pre-incision recruitment of NER factors is impaired by the presence of the third DNA strand. These data characterize triplex-induced modulation of ICL repair pathways at specific steps, which might have implications for the controlled induction of targeted genomic modifications and for the associated cellular responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966263      PMCID: PMC373402          DOI: 10.1093/nar/gkh267

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  41 in total

1.  DNA repair activity in protein extracts from rat tissues.

Authors:  F Coudoré; P Calsou; B Salles
Journal:  FEBS Lett       Date:  1997-09-15       Impact factor: 4.124

2.  DNA damage recognition by XPA protein promotes efficient recruitment of transcription factor II H.

Authors:  S Nocentini; F Coin; M Saijo; K Tanaka; J M Egly
Journal:  J Biol Chem       Date:  1997-09-12       Impact factor: 5.157

3.  Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts.

Authors:  J G Moggs; D E Szymkowski; M Yamada; P Karran; R D Wood
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

4.  Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair.

Authors:  G Wang; M M Seidman; P M Glazer
Journal:  Science       Date:  1996-02-09       Impact factor: 47.728

5.  Initiation of DNA interstrand cross-link repair in humans: the nucleotide excision repair system makes dual incisions 5' to the cross-linked base and removes a 22- to 28-nucleotide-long damage-free strand.

Authors:  T Bessho; D Mu; A Sancar
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

6.  Specific inhibition of in vitro transcription elongation by triplex-forming oligonucleotide-intercalator conjugates targeted to HIV proviral DNA.

Authors:  C Giovannangeli; L Perrouault; C Escudé; T Nguyen; C Hélène
Journal:  Biochemistry       Date:  1996-08-13       Impact factor: 3.162

7.  Sequential binding of DNA repair proteins RPA and ERCC1 to XPA in vitro.

Authors:  M Saijo; I Kuraoka; C Masutani; F Hanaoka; K Tanaka
Journal:  Nucleic Acids Res       Date:  1996-12-01       Impact factor: 16.971

8.  Detection of covalent triplex within human cells.

Authors:  A L Guieysse; D Praseuth; M Grigoriev; A Harel-Bellan; C Hélène
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

9.  Stable triple helices formed by oligonucleotide N3'-->P5' phosphoramidates inhibit transcription elongation.

Authors:  C Escudé; C Giovannangeli; J S Sun; D H Lloyd; J K Chen; S M Gryaznov; T Garestier; C Hélène
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant.

Authors:  M Raha; G Wang; M M Seidman; P M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

View more
  5 in total

Review 1.  Triplex technology in studies of DNA damage, DNA repair, and mutagenesis.

Authors:  Anirban Mukherjee; Karen M Vasquez
Journal:  Biochimie       Date:  2011-04-11       Impact factor: 4.079

Review 2.  Repair of DNA lesions associated with triplex-forming oligonucleotides.

Authors:  Joanna Y Chin; Peter M Glazer
Journal:  Mol Carcinog       Date:  2009-04       Impact factor: 4.784

3.  Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication.

Authors:  Koji Nakanishi; Francesca Cavallo; Loïc Perrouault; Carine Giovannangeli; Mary Ellen Moynahan; Marco Barchi; Erika Brunet; Maria Jasin
Journal:  Nat Struct Mol Biol       Date:  2011-03-20       Impact factor: 15.369

4.  Triplex targeted genomic crosslinks enter separable deletion and base substitution pathways.

Authors:  Sally Richards; Su-Ting Liu; Alokes Majumdar; Ji-Lan Liu; Rodney S Nairn; Michel Bernier; Veronica Maher; Michael M Seidman
Journal:  Nucleic Acids Res       Date:  2005-09-25       Impact factor: 16.971

5.  Human XPC-hHR23B interacts with XPA-RPA in the recognition of triplex-directed psoralen DNA interstrand crosslinks.

Authors:  Brian S Thoma; Mitsuo Wakasugi; Jesper Christensen; Madhava C Reddy; Karen M Vasquez
Journal:  Nucleic Acids Res       Date:  2005-05-24       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.